Opinion|Videos|July 17, 2024
Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024
Author(s)Joseph Mikhael, MD
Dr. Mikhael discusses treatment in early relapse of multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- Please discuss recent updates presented at EHA 2024 in early-relapse multiple myeloma from CARTITUDE-4, KARMMA-2, DREAMM-7, and DREAMM-8.
Advertisement
Related to this article
North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Access and Innovation in North Carolina’s Research Triangle
3
Biomarker-Driven Care Is Racing Ahead of the Systems Built to Support It
4
Overcoming Barriers to Precision Care and Patient Access
5